Literature DB >> 22939618

Single-stranded siRNAs activate RNAi in animals.

Walt F Lima1, Thazha P Prakash, Heather M Murray, Garth A Kinberger, Wenyu Li, Alfred E Chappell, Cheryl S Li, Susan F Murray, Hans Gaus, Punit P Seth, Eric E Swayze, Stanley T Crooke.   

Abstract

The therapeutic utility of siRNAs is limited by the requirement for complex formulations to deliver them to tissues. If potent single-stranded RNAs could be identified, they would provide a simpler path to pharmacological agents. Here, we describe single-stranded siRNAs (ss-siRNAs) that silence gene expression in animals absent lipid formulation. Effective ss-siRNAs were identified by iterative design by determining structure-activity relationships correlating chemically modified single strands and Argonaute 2 (AGO2) activities, potency in cells, nuclease stability, and pharmacokinetics. We find that the passenger strand is not necessary for potent gene silencing. The guide-strand activity requires AGO2, demonstrating action through the RNAi pathway. ss-siRNA action requires a 5' phosphate to achieve activity in vivo, and we developed a metabolically stable 5'-(E)-vinylphosphonate (5'-VP) with conformation and sterioelectronic properties similar to the natural phosphate. Identification of potent ss-siRNAs offers an additional option for RNAi therapeutics and an alternate perspective on RNAi mechanism.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939618     DOI: 10.1016/j.cell.2012.08.014

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  111 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

2.  Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.

Authors:  W Brad Wan; Michael T Migawa; Guillermo Vasquez; Heather M Murray; Josh G Nichols; Hans Gaus; Andres Berdeja; Sam Lee; Christopher E Hart; Walt F Lima; Eric E Swayze; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2014-11-14       Impact factor: 16.971

Review 3.  Strategies, design, and chemistry in siRNA delivery systems.

Authors:  Yizhou Dong; Daniel J Siegwart; Daniel G Anderson
Journal:  Adv Drug Deliv Rev       Date:  2019-05-15       Impact factor: 15.470

4.  Modulation of Splicing by Single-Stranded Silencing RNAs.

Authors:  Jing Liu; Jiaxin Hu; Jessica A Hicks; Thazha P Prakash; David R Corey
Journal:  Nucleic Acid Ther       Date:  2015-03-10       Impact factor: 5.486

Review 5.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

Review 6.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 7.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

8.  Argonaute-bound small RNAs from promoter-proximal RNA polymerase II.

Authors:  Jesse R Zamudio; Timothy J Kelly; Phillip A Sharp
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

Review 9.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

10.  Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion.

Authors:  Xiulong Shen; Audrius Kilikevicius; Daniel O'Reilly; Thazha P Prakash; Masad J Damha; Frank Rigo; David R Corey
Journal:  Bioorg Med Chem Lett       Date:  2018-07-21       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.